Cargando…

Overcoming EGFR inhibitor resistance in Glioblastoma by targeting co-amplified genes

Detalles Bibliográficos
Autores principales:	Pant, Ayush, Lim, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	National Academy of Sciences 2023
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10515143/ https://www.ncbi.nlm.nih.gov/pubmed/37672559 http://dx.doi.org/10.1073/pnas.2312277120

Ejemplares similares

Co-Targeting the EGFR and PI3K/Akt Pathway to Overcome Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma: What about Autophagy?
por: Zaryouh, Hannah, et al.
Publicado: (2022)

The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma
por: Liu, Xuejiao, et al.
Publicado: (2019)

Overcoming resistance to PARP inhibitor in epithelial ovarian cancer, are we ready?
por: Ray-Coquard, Isabelle, et al.
Publicado: (2020)

Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors
por: Nanjo, Shigeki, et al.
Publicado: (2013)

Targeting the translational machinery to overcome apoptosis resistance in pancreatic cancer
por: Wirth, Matthias
Publicado: (2022)

Targeting Autophagy for Overcoming Resistance to Anti-EGFR Treatments
por: Kwon, Yoojung, et al.
Publicado: (2019)

Emerging strategies to overcome resistance to third-generation EGFR inhibitors
por: Shi, Kunyu, et al.
Publicado: (2022)

HSP70 and FLT3-ITD: Targeting chaperone system to overcome drug resistance
por: Yang, Jing, et al.
Publicado: (2021)

Alterations in 3D chromatin organization contribute to tumorigenesis of EGFR-amplified glioblastoma
por: Yang, Qi, et al.
Publicado: (2022)

Sodium iodide symporter-targeted gene therapy in glioblastoma
por: Nicola, Juan Pablo, et al.
Publicado: (2023)

Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
por: Yang, Lu, et al.
Publicado: (2022)

Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer
por: Yochum, Zachary A., et al.
Publicado: (2018)

Genomic instability as a major mechanism for acquired resistance to EGFR tyrosine kinase inhibitors in cancer
por: Liu, Bing, et al.
Publicado: (2021)

Trans-amplifying RNA: Translational application in gene therapy
por: Lundstrom, Kenneth
Publicado: (2023)

Overcoming EGFR T790M and C797S resistance with mutant-selective allosteric inhibitors
por: Jia, Yong, et al.
Publicado: (2016)

Supercharged chimeric antigen receptor T cells in solid tumors
por: Pant, Ayush, et al.
Publicado: (2022)

Dissecting the Methylomes of EGFR-Amplified Glioblastoma Reveals Altered DNA Replication and Packaging, and Chromatin and Gene Silencing Pathways
por: Kraus, Theo F. J., et al.
Publicado: (2023)

Overcoming Resistance to AC0010, a Third Generation of EGFR Inhibitor, by Targeting c-MET and BCL-2
por: Xu, Wanhong, et al.
Publicado: (2018)

Re-enforcing the strategy of targeting MEK/ERK signaling to overcome acquired resistance to third generation EGFR inhibitors
por: Zhao, Wen, et al.
Publicado: (2021)

Barriers to overcoming immunotherapy resistance in glioblastoma
por: Gillette, Julia S., et al.
Publicado: (2023)

Overcoming TRAIL Resistance for Glioblastoma Treatment
por: Deng, Longfei, et al.
Publicado: (2021)

Mechanisms of EGFR Resistance in Glioblastoma
por: Pan, Peter C., et al.
Publicado: (2020)

COVID-19: exposing and amplifying inequalities
por: Marmot, Michael, et al.
Publicado: (2020)

Overcoming EGFR(G724S)-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
por: Fassunke, Jana, et al.
Publicado: (2018)

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
por: Canonici, Alexandra, et al.
Publicado: (2013)

Caspase-8: A Novel Target to Overcome Resistance to Chemotherapy in Glioblastoma
por: Fianco, Giulia, et al.
Publicado: (2018)

Targeting the DNA Damage Response to Overcome Cancer Drug Resistance in Glioblastoma
por: Ferri, Alessandra, et al.
Publicado: (2020)

Targeting Tumor Associated Macrophages to Overcome Conventional Treatment Resistance in Glioblastoma
por: Grégoire, Hélène, et al.
Publicado: (2020)

DDRE-24. TARGETING PURINE METABOLISM TO OVERCOME GLIOBLASTOMA THERAPY RESISTANCE
por: Zhou, Weihua, et al.
Publicado: (2021)

An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors
por: Mancini, Maicol, et al.
Publicado: (2017)

Losmapimod: A Novel Clinical Drug to Overcome Gefitinib-Resistance
por: Nishimura, Yukio
Publicado: (2018)

Deciphering the true antiproliferative target of an MK2 activation inhibitor in glioblastoma
por: Brennan, P E
Publicado: (2016)

Overcoming acquired resistance of EGFR‐mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol
por: Zang, Hongjing, et al.
Publicado: (2020)

Co-administration of MDR1 and BCRP or EGFR/PI3K inhibitors overcomes lenvatinib resistance in hepatocellular carcinoma
por: Sun, Dawei, et al.
Publicado: (2022)

A nanotherapeutic strategy to target drug‐tolerant cells and overcome EGFR tyrosine kinase inhibitor resistance in lung cancer
por: Shaurova, Tatiana, et al.
Publicado: (2023)

Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma
por: JIAPAER, Shabierjiang, et al.
Publicado: (2018)

Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial
por: Lassman, Andrew B, et al.
Publicado: (2022)

EGFR and mTOR as therapeutic targets in glioblastoma
por: Ronellenfitsch, Michael W., et al.
Publicado: (2019)

Modeling therapy resistance via the EGFR signaling pathway
por: Plattner, Christina, et al.
Publicado: (2019)

Novel agents and strategies for overcoming EGFR TKIs resistance
por: Niu, Fei-Yu, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_9sfjgbnvn5fje0h4k743uuj0l7